Polymorphic changes in the KAL1 gene: Not all of them should be classified as polymorphisms

Journal of Endocrinological Investigation

Volumn 27, Issue 8, 2004, Pages 765-769

  Soderlund D ^a   Vilchis, F ^b   Mendez J P ^a,c  

^a HOSPITAL DE PEDIATRÍA   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Hypogonadism; KAL1 gene; Kalimann; Polymorphisms; Pseudogene

Indexed keywords

GENE PRODUCT; PROTEIN KAL1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KALLMANN SYNDROME; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POSITION EFFECT; PSEUDOGENE; TURNER SYNDROME; X CHROMOSOME; Y CHROMOSOME;

EID: 10244235361     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347520     Document Type: Article

References (25)

1. Ballabio A, Andria G. Deletions and translocations involving the distal short arm of the human X chromosome: review and hypotheses. Hum Mol Genet 1992, 1: 221-7.
2. Franco B, Guioli S, Pragliola A, et al. A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules. Nature 1991, 353: 529-36.
3. Legouis R, Hardelin J-P, Levilliers J, et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 1991, 67: 423-35.
4. Weissenbach J, Goodfellow PN, Smith KD. Report of the committee on the genetic constitution of the Y chromosome. Cytogenet Cell Genet 1989, 51: 438-49.
5. Incerti B, Guioli S, Pragliola A, et al. Kallmann syndrome gene on the X and Y chromosomes: implications for evolutionary divergence of human sex chromosomes. Nat Genet 1992, 2: 311-4.
6. Maya-Núñez G, Zenteno JC, Ulloa-Aguirre A, Kofman-Alfaro S, Méndez JP. A recurrent missense mutation in the KAL gene in patients with X-linked Kallmann's syndrome. J Clin Endocrinol Metab 1998, 83: 1650-3.
7. Maya-Núñez G, Cuevas-Covarrubias S, Zenteno JC, Ulloa-Aguirre A, Kofman-Alfaro S, Méndez JP. Contiguous gene syndrome due to deletion of the first three exons of the Kallmann gene and complete deletion of the steroid sulphatase gene. Clin Endocrinol (Oxf) 1998, 48: 713-8.
8. Maya-Núñez G, Torres L, Ulloa-Aguirre A, et al. An atypical contiguous gene syndrome: molecular studies in a family with X-linked Kallmann syndrome and X-linked ichthyosis. Clin Endocrinol (Oxf) 1999, 50: 157-62.
9. Söderlund D, Canto P, Méndez JP. Identification of three novel mutationsinthe KAL1 gene in patients with Kallmann syndrome. J Clin Endocrinol Metab 2002, 87: 2589-92.
10. Hardelin J-P, Levilliers J, Blanchard S, et al. Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome. Hum Mol Genet 1993, 2: 373-7.
11. Oliveira LMB, Seminara SB, Beranova M, et al. The importance of autosomal genes in Kallmann syndrome: genotypephenotype correlations and neuroendocrine characteristics. J Clin Endocrinol Metab 2001, 86: 1532-8.
12. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press 2001, vol 1, pp 6.4-6.12.
13. Hardelin J-P, Levilliers J, Young J, et al. Xp22.3 deletions in isolated familial Kallmann's syndrome. J Clin Endocrinol Metab 1993, 76: 827-31.
14. Vilchis F, Hernández D, Canto P, Méndez JP, Chávez B. Codon 89 polymorphism of the human 5α-reductase type 2 gene. Clin Genet 1997, 51: 399-402.
15. Makridakis N, Ross RK, Pike MC, et al. A prevalent missense substitution that modulates activity of prostatic steroid 5α -reductase. Cancer Res 1997, 57: 1020-2.
16. Makridakis NM, Ross RK, Pike MC, et al. Association of missense substitution in SR5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 1999, 354: 975-8.
17. Mononen N, Ikonen T, Syrjäkoski K, et al. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Bri J Cancer 2001, 84: 1344-7.
18. del Castillo I, Cohen-Salmon M, Blanchard S, Lutfalla G, Petit C. Structure of the X-linked Kallmann syndrome gene and its homologous pseudogene on the Y chromosome. Nat Genet 1992, 2: 305-10.
19. White PC, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci USA 1986, 83: 5111-5.
20. Lee HH, Chao HT, Ng HT, Choo KB. Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. J Med Genet 1996, 33: 371-5.
21. Alloisio N, Morlé L, Maréchal J, et al. Sp alpha V/41: a common spectrin polymorphism at the alpha IV-alpha V domain junction. Relevance to the expression level of hereditary elliptocytosis due to alpha-spectrin variants located in trans. J Clin Invest 1991, 87: 2169-77.
22. Goldfarb LG, Petersen RB, Tabaton M, etal. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science 1992, 258: 806-8.
23. Rau H, Braun J, Donner H, et al. The codon 17 polymorphism of the CTLA4 gene in type 2 diabetes mellitus. J Clin Endocrinol Metab 2001, 86: 653-5.
24. Tsuge T, Shimokawa T, Horikoshi S, Tomino Y, Ra C. Polymorphism in promoter region of Fc alpha receptor gene in patients with IgA nephropathy. Hum Genet 2001, 108: 128-33.
25. Yamada R, Tanaka T, Unoki M, et al. Association between a single-nucleotide polymorphism in the promoter of the human interleukin-3 gene and rheumatoid arthritis in Japanese patients, and maximum-likelihood estimation of combinatorial effect that two genetic loci have on susceptibility to the disease. Am J Med Genet 2001, 68: 674-85.